Sign In
Buy BNTX
$91.35
-0.90 (-0.98%)
At Close: Aug 04, 2026
New York State's recent COVID case surge caused by two new versions of omicron that are even more infectious than BA.2
05:35pm, Thursday, 14'th Apr 2022 MarketWatch
A surge of COVID-19 cases in New York State that is making it once again an epicenter of the U.S. pandemic is due to two new versions of the omicron variant, that appear even more infectious than the
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11
Pfizer Inc (
Pfizer und BioNTech veröffentlichen Daten zu starker Immunantwort nach Auffrischungsimpfung mit dem COVID-19-Impfstoff bei Kindern im Alter von 5 bis 11 Jahren
10:45am, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
NEW YORK und MAINZ, Deutschland, 14. April 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute positive Ergebnisse einer klinischen Phase-2/3-Stud
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
10:45am, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
NEW YORK and MAINZ, Germany, April 14, 2022 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive results from a Phase 2/3 clinical trial ev
Pfizer and BioNTech say data shows high immune response for COVID booster in children aged 5 to 11
06:56am, Thursday, 14'th Apr 2022
Pfizer Inc. PFE, -0.02% and German partner BioNTech SE BNTX, +6.06% said Thursday a Phase 2/3 trial of their COVID-19 vaccine booster showed a high immune response in children aged 5-to-11-years old.
Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study
01:55pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.
2 Unbelievable Clues That Biotech Revenue May Soon Rival Big Pharma
11:00am, Wednesday, 13'th Apr 2022 The Motley Fool
Biotech today makes us think of blockbuster products.
HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target
06:55pm, Tuesday, 12'th Apr 2022 Benzinga
HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price target to $298 from the prior $339.
The analyst noted initial data of BNT211, an autologous CAR-
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
06:51pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
04:33pm, Tuesday, 12'th Apr 2022
Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
mRNA Cancer Treatment: Covid Vaccine Giant BioNTech Touts Promising Early Data
12:49pm, Monday, 11'th Apr 2022
An mRNA vaccine can potentially boost cell treatments used to fight blood cancer and make them more effective in solid tumors, BioNTech said, citing early data.
Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
11:54am, Monday, 11'th Apr 2022
BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprieta
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
11:00am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
MAINZ, Germany and BEDMINSTER, New Jersey (USA), April 11, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Matinas BioPharma (NYSE AMER: MTNB, “Matinas”), a clinical-stage biopharmaceuti
BioNTech und Matinas BioPharma geben exklusive Forschungskollaboration zur Entwicklung neuer Formulierungen für mRNA-basierte Impfstoffe bekannt
11:00am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
MAINZ, Deutschland und BEDMINSTER, New Jersey (USA), 11. April 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) und Matinas BioPharma (NYSE AMER: MTNB, “Matinas”), ein biopharmazeutisches Unt
BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
07:55am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
MAINZ, Germany, April 11, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) presented data from its ongoing first-in-human Phase 1/2 trial evaluating the safet
